Recursion Pharmaceuticals Provides Pipeline Updates and Prepares for Q3 2026 Earnings
Recursion Pharmaceuticals announced updates to its TUPELO study for REC-4881 and gave progress reports on its wider clinical pipeline ahead of its third-quarter 2026 earnings release, according to the report.
tradingview.com ·